A breast cancer drug at the center of a prolonged pricing row in Britain will now be paid for routinely following a discount deal between Roche and the NHS.
EULAR 2017: Lilly’s Taltz (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
Eli Lilly and Company announced that patients with active psoriatic arthritis who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with Taltz (ixekizumab) achieved significant improvement in signs and symptoms of their disease at 24 weeks when compared to placebo.
Republican senators trying to repeal Obamacare are forming consensus to keep some of the U.S. healthcare law’s taxes they long criticized, in hopes of delaying more drastic funding cuts, particularly to the Medicaid program for the poor and disabled.
Tazemetostat – an experimental Phase II treatment for lymphomas – showed a 29 percent overall response rate in patients with DLBCL, below investors’ expectations.
Startup biotech companies have a new place to call home in downtown Manhattan thanks to Alexandria Real Estate Equities.
NPEC is among the essay contest scholarships that’s certainly available to senior high school pupils. One scholarship specially is an essay contest. If you’re trying to find scholarship essay competitions are rushessay.com discounts confident you go through everything which is supplied about the contest, by way of example, qualification criteria along with the required output. […]
Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.
Janssen Presents Long Term Phase 3 Efficacy and Safety Data of Sirukumab in Rheumatoid Arthritis Patients Who had an Inadequate Response and/or Who Were Intolerant to Anti-TNFs
Janssen-Cilag International NV today announced long-term results from SIRROUND-T, a pivotal Phase 3 study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumor necrosis factor (TNF)-alpha treatments.
J&J said its experimental flu drug significantly reduced the presence of the virus in patients with a type of influenza in a mid-stage study.
Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to Humira
Boehringer Ingelheim announced results from the pivotal Phase III VOLTAIRE-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and Humira have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis.